Late last year, Acorn Cardiovascular, a New Brighton, Minnesota company, liquidated its assets and formally shut down. It had capitulated to the U.S. Food and Drug Administration from which it could not win a pre-market application approval for a mesh device to support the heart. Since 2002, the company had raised $100 million.Steve Anderson, Acorn’s [...]